Seaport Therapeutics Q3 net loss widens 17% to $26.39 million

PUBT · 1d ago
Seaport Therapeutics Q3 net loss widens 17% to $26.39 million
  • Seaport Therapeutics’ third-quarter 2026 net loss widened 17% year over year to $26.39 million.
  • Research and development expenses rose 17% to $23.89 million, primarily due to higher clinical development spending for GlyphAllo’s BUOY-1 trial.
  • Cash, cash equivalents and investments totaled $403.8 million at September 30, 2026, with funding expected to support operations into 2029.
  • Enrollment remains on track in GlyphAllo’s Phase 2b BUOY-1 depression trial, with topline data expected in the first half of 2027.
  • A potentially registration-enabling GlyphAgo Phase 2/3 anxiety trial is planned for the first half of 2027, with results expected by year-end 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seaport Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261102054810) on November 02, 2026, and is solely responsible for the information contained therein.